Table 1 Patient characteristics by cases and controls
From: Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancer
Cases | Controls | All Patients | P-value | |
|---|---|---|---|---|
(N = 194) | (N = 221) | (N = 415) | ||
Institution | <0.001 | |||
Cornell | 31 (16.0%) | 0 (0%) | 31 (7.5%) | |
Montefiore | 66 (34.0%) | 114 (51.6%) | 180 (43.4%) | |
MSKCC | 73 (37.6%) | 84 (38.0%) | 157 (37.8%) | |
NYU | 24 (12.4%) | 23 (10.4%) | 47 (11.3%) | |
Race | 0.19 | |||
White | 82 (42.3%) | 63 (28.5%) | 145 (34.9%) | |
Black | 76 (39.2%) | 108 (48.9%) | 184 (44.3%) | |
Asian | 5 (2.6%) | 6 (2.7%) | 11 (2.7%) | |
Other | 31 (16.0%) | 44 (19.9%) | 75 (18.1%) | |
Age (years) | 0.68 | |||
Mean (SD) | 56.0 (13.1) | 56.8 (13.3) | 56.4 (13.2) | |
Median [Min, Max] | 55.0 [26.0, 89.0] | 56.0 [27.0, 89.0] | 56.0 [26.0, 89.0] | |
Body Mass Index | 0.81 | |||
Mean (SD) | 29.5 (6.66) | 29.2 (6.26) | 29.3 (6.43) | |
Median [Min, Max] | 28.2 [18.7, 56.8] | 28.8 [15.4, 51.7] | 28.6 [15.4, 56.8] | |
Missing | 33 (17.0%) | 3 (1.4%) | 36 (8.7%) | |
Surgery type | 0.51 | |||
BCT/Lumpectomy | 107 (55.2%) | 140 (63.3%) | 247 (59.5%) | |
Lumpectomy followed by mastectomy | 8 (4.1%) | 7 (3.2%) | 15 (3.6%) | |
Mastectomy | 79 (40.7%) | 72 (32.6%) | 151 (36.4%) | |
Missing | 0 (0%) | 2 (0.9%) | 2 (0.5%) | |
Radiation | 0.31 | |||
Yes | 127 (65.5%) | 158 (71.5%) | 285 (68.7%) | |
No | 62 (32.0%) | 55 (24.9%) | 117 (28.2%) | |
Missing | 5 (2.6%) | 8 (3.6%) | 13 (3.1%) | |
Tumor stage (pT) | <0.001 | |||
T1 ( < 2 cm) | 77 (39.7%) | 136 (61.5%) | 213 (51.3%) | |
T2 (2-5 cm) | 102 (52.6%) | 81 (36.7%) | 183 (44.1%) | |
T3 ( > 5 cm) | 15 (7.7%) | 4 (1.8%) | 19 (4.6%) | |
Lymph node status (pN) | <0.001 | |||
Positive | 116 (59.8%) | 82 (37.1%) | 198 (47.7%) | |
Negative | 73 (37.6%) | 132 (59.7%) | 205 (49.4%) | |
Missing | 5 (2.6%) | 7 (3.2%) | 12 (2.9%) | |
Tumor grade | <0.001 | |||
High | 145 (74.7%) | 105 (47.5%) | 250 (60.2%) | |
Low-intermediate | 49 (25.3%) | 113 (51.1%) | 162 (39.0%) | |
Missing | 0 (0%) | 3 (1.4%) | 3 (0.7%) | |
Subtype | 0.86 | |||
ER + /HER2- | 118 (60.8%) | 146 (66.1%) | 264 (63.6%) | |
TNBC | 50 (25.8%) | 51 (23.1%) | 101 (24.3%) | |
HER2+ | 26 (13.4%) | 24 (10.9%) | 50 (12.0%) |
